Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
Om

Menu

Close

EffektEffektdataStudiedesignKlinisk remisjonTidlig symptomatisk responsEndoskopisk forbedringBiologiske/JAKi-undergrupperIsolert proktittSikkerhetBivirkningerHjerte- og øyebivirkningerKom i gangOpplæringsmateriellMateriellVideo
Biologiske/JAKi-undergrupper

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

First-line advanced therapy* use supported by VELSIPITY efficacy in biologic/JAKi subgroupsPatients on VELSIPITY achieved clinical remission in both the biologic/JAKi-naive and biologic/JAKi-exposed subgroups in ELEVATE UC 521,2
Graph made by Pfizer from data in ref 1 table 2 and ref 2 table S5
 
Advanced therapies include S1P receptor modulators, biologics, and JAK inhibitors.3Clinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Analysis of outcomes by prior treatment was not powered for statistical significance.3 Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
First-line advanced therapy* use supported by VELSIPITY efficacy in biologic/JAKi subgroupsPatients on VELSIPITY achieved clinical remission in both the biologic/JAKi-naive and biologic/JAKi-exposed subgroups in ELEVATE UC 121,2
Graph made by Pfizer from data in ref 1 table 3 and ref 2 table S8
 
Advanced therapies include S1P receptor modulators, biologics, and JAK inhibitors.3Clinical remission was defined as a stool frequency (SF) subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding (RB) subscore of 0, and an endoscopy score (ES) ≤1 (excluding friability).1Analysis of outcomes by prior treatment was not powered for statistical significance.3
Clinical remission was controlled for multiplicity via parallel gatekeeping procedures that preserved the type I error rate at 5%.3
References:VELSIPITY (etrasimod) Summary of Product Characteristics.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171.
Isolated Proctitis

See how VELSIPITY is effective in calming the chaos of isolated proctitis.

 Isolert proktittLoading

Preparatomtale

 
PP-V1A-NOR-0013 | Utarbeidet 08.2024

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei